Valuation: Charles River Laboratories International, Inc.

Market Cap 1.62TCr 1.44TCr 1.33TCr 1.2TCr 2.26TCr 1,53100Cr 2.32TCr 16TCr 6.37TCr 81TCr 6.07TCr 5.94TCr 2,56100Cr P/E 2026 *
84x
P/E 2027 * 36.2x
Enterprise Value 1.83TCr 1.63TCr 1.5TCr 1.36TCr 2.56TCr 1,73000Cr 2.62TCr 18TCr 7.2TCr 91TCr 6.86TCr 6.71TCr 2,89500Cr EV / Sales 2026 *
4.66x
EV / Sales 2027 * 4.45x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -
27/10 Charles River Laboratories International, Inc. Announces Collaboration with Ipsen to Leverage Virtual Control Groups in Good Laboratory Practice-Compliant Study CI
27/10 Charles River Laboratories International Insider Sold Shares Worth $8,414,700, According to a Recent SEC Filing MT
23/10 Labcorp, Charles River Laboratories and U.S. Food and Drug Administration Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential CI
14/10 JPMorgan Adjusts Price Target on Charles River Laboratories International to $345 From $310 MT
13/10 Magellan Stem Cells Collaborates with Charles River Laboratories International, Inc. to Advance Stem Cell and Regenerative Medicine Development CI
13/10 Charles River Laboratories Working With Magellan Stem Cells to Test Osteoarthritis Therapy MT
12/10 Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $340 From $300 MT
06/10 Charles River Laboratories International, Inc. and Autolomous Launch Apollo Orchestrate Within Charles River's Apollo Platform CI
30/09 UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175 MT
29/09 PMGC Unit Working With Charles River Laboratories for Muscle Health Probiotic Testing MT
28/09 Jefferies Adjusts PT on Charles River Laboratories International to $340 From $305, Maintains Buy Rating MT
25/09 Charles River Laboratories's DAS Segment Faces Largest Margin Upside, RBC Says MT
25/09 Deutsche Bank Raises Price Target on Charles River Laboratories International to $320 From $300, Keeps Buy Rating MT

Last Transcript: Charles River Laboratories International, Inc.

1 day+4.17%
1 week-1.07%
Current month-1.22%
1 month+14.24%
3 months+53.77%
6 months+106.02%
Current year+77.97%
1 week 337.37
Extreme 337.37
379.63
1 month 288.42
Extreme 288.425
379.63
Current year 146.2
Extreme 146.195
379.63
1 year 146.2
Extreme 146.195
379.63
3 years 91.86
Extreme 91.8609
379.63
5 years 91.86
Extreme 91.8609
397.77
10 years 67.36
Extreme 67.36
460.21
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Date Insider Type Main position Quantity % Market Cap. Importance
05/10/26 Exercice

Executive/Senior Manager

2,943 0.0062%
30/09/26 Buy

Chief Financial Officer

10 0.0000%
25/08/26 Exercice

Director

1,00,683 0.2090%
Change 5-day change 1-year change 3-year change Capi.($)
+4.17%-1.07%+98.49%+95.16% 1.62TCr
-2.43%-7.34%+36.10%+58.44% 6.22TCr
+0.61%+0.77%+11.13%+69.42% 5.49TCr
+0.62%+2.58%+20.96%+98.18% 5.53TCr
+1.49%-3.33%+22.73%+33.11% 4.26TCr
-1.36%-2.76%+14.14%+93.69% 4.11TCr
+3.55%+4.01%+226.45%+774.01% 4.03TCr
+0.57%+24.09%+99.46%+84.11% 3.31TCr
-1.09%-0.05%+13.55%+45.35% 3.26TCr
-3.22%+11.14%-43.33%+324.69% 2.4TCr
Average +0.30%+2.85%+49.97%+167.62% 4.02TCr
Weighted average by Cap. +0.12%+1.82%+47.20%+156.46%

Financials

2026 *2027 *
Net sales 391.7Cr 349.95Cr 321.45Cr 291.94Cr 548.24Cr 37TCr 562.01Cr 3.84TCr 1.54TCr 20TCr 1.47TCr 1.44TCr 62TCr 401.61Cr 358.8Cr 329.58Cr 299.33Cr 562.11Cr 38TCr 576.23Cr 3.93TCr 1.58TCr 20TCr 1.51TCr 1.48TCr 64TCr
Net income 19Cr 17Cr 15Cr 14Cr 26Cr 1.77TCr 27Cr 183.2Cr 74Cr 935.04Cr 70Cr 69Cr 2.96TCr 44Cr 39Cr 36Cr 33Cr 61Cr 4.14TCr 63Cr 427.87Cr 172.12Cr 2.18TCr 163.95Cr 160.44Cr 6.92TCr
Net Debt 210.47Cr 188.03Cr 172.72Cr 156.86Cr 294.58Cr 20TCr 301.98Cr 2.06TCr 829.36Cr 11TCr 789.99Cr 773.09Cr 33TCr 172.46Cr 154.08Cr 141.53Cr 128.54Cr 241.39Cr 16TCr 247.45Cr 1.69TCr 679.61Cr 8.62TCr 647.35Cr 633.5Cr 27TCr
Projected Income Statement - Annual - Charles River Laboratories International, Inc.
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change Volume
04/26/04 $353.35 +4.37% 7,31,127
02/26/02 $338.54 -5.81% 16,20,581
30/26/30 $359.41 -4.44% 15,03,507
29/26/29 $376.10 +0.57% 8,87,341
28/26/28 $373.98 +4.22% 12,99,416
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Charles River Laboratories International, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
338.54USD
Average target price
318.87USD
Spread / Average Target
-5.81%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Charles River Laboratories International, Inc.